FILTER
FILTERED INTERVIEW RESULTS
John Patrick Oroho
EXECUTIVE VICE PRESIDENT & CHIEF STRATEGY OFFICER, PORZIO LIFE SCIENCES LLC
Porzio Life Sciences LLC explains how it helps pharma companies with complex reporting requirements.
Brad Payne & Chris Blanton & Morgan Brandt
COO & VP AND GENERAL MANAGER & GLOBAL DIRECTOR, DIGITAL PRODUCTS, PCI PHARMA SERVICES
PCI Pharma Services relates its rapid expansion in both services and geography.
Johnson Lai
VP, CHEMICAL SPECIALTIES LIMITED (CSL)
CSL explains how it can help MNCs quickly grow their manufacturing footprint in Asia to tap into the fast-developing APAC and Middle Eastern markets with minimal capital investment.
Riccardo Palmisano
PRESIDENT, ASSOBIOTEC
Federchimica Assobiotec explains how the association is striving to help Italy’s biotech industry reach the scale that its’ potential offers.
Giovanni Sala
GENERAL MANAGER, MEDAC PHARMA
Medac Pharma explains how producers of original drugs struggle to gain a fair price in Italy.
Enrique Hausermann
PRESIDENT, EGUALIA
Egualia is the Italian association for generics, biosimilars and VMAs and comments on some of the challenges that its’ members face.
Michael Quirmbach
CEO & PRESIDENT, CORDENPHARMA
CordenPharma is enjoying great demand for its increasing array of services.
Alan Petro
CEO, NEW VISION PHARMACEUTICALS
New Vision Pharmaceuticals explains how it is developing Blow-Fill-Seal technology and other services.
Luca Candioli
OWNER & GENERAL MANAGER, CANDIOLI PHARMA
Italian animal health company Candioli explains how it intends to double in size during the next five years.
Paolo Tubertini
CEO, OLON
Olon has expanded from production of APIs and intermediates to include CDMO and Biotech operations in Italy and beyond.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
